Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q1 2026 Earnings Presentation
9 slides from Avita Medical's earnings presentation, May 18, 2026
Slide 1: AVITA Medical First Quarter 2026 Briefing
For personal use only May 2026 AVITA Medical First Quarter 2026 Briefing Cary Vance, President and CEO David O’Toole, CFO (ASX: AVH, NASDAQ: RCEL)
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These For personal use only statements are predictions and subject to si
Slide 3: Actions taken over the past two quarters are now translating into performance
Actions taken over the past two quarters are now translating into performance For personal use only Stabilized the business and Improved operating Q1 marks a transition to re-established consistent, execution through focused more consistent and procedure-driven demand commercial strategy and predict
Slide 4: AVITA delivered a solid start to the year while advancing new product data and clinical experience
AVITA delivered a solid start to the year while advancing new product data and clinical experience Net revenue For personal use only Q1 product highlights in USD millions • Secured 10-year BARDA* deal (up to $25.5M, with ~10% $3.8M guaranteed), delivering recurring readiness revenue, strengthens U.S
Slide 5: ALL seven Medicare Administrative Contractors published ABA-recommended rates for clinician use of RECELL
ALL seven Medicare Administrative Contractors published ABA- recommended rates for clinician use of RECELL RECELL provider reimbursement and data are now aligned to restore use and adoption For personal use only Medicare Administrative Contractors Reimbursement Data Predictable payment Clinical Clin
Slide 6: Cohealyx I interim data demonstrates ~20-day reduction in time to skin graft readiness
Cohealyx I interim data demonstrates ~20-day reduction in time to skin graft readiness with strong surgeon validation Primary endpoint: Time to skin grafting Cohealyx demonstrates reduction in time to skin graft readiness For personal use only compared to objective performance goal1 13.6 days vs. 33
Slide 7: Q1 2026 reflects momentum from 2025, with improving performance versus prior year
Q1 2026 reflects momentum from 2025, with improving performance versus prior year Year-over-year Q1 comparison Sequential quarterly trend in USD millions For personal use only Key figures Q1 Q1 Q2 Q3 Q4 2026 2025 2025 2025 2025 Revenue $19.3 $18.5 $18.4 $17.1 $17.6 Gross profit margin 81.7%* 84.7% 8
Slide 8: Summary
Summary For personal use only Delivered solid Q1 Exited Q1 with Generated compelling Positioned for revenue performance consistent, procedure- Cohealyx clinical data repeatable quarterly driven by improving driven demand and ~20-day reduction in growth in 2026 with a RECELL utilization, ordering pat
Slide 9: For personal use only
For personal use only